business address: 1550 orleans street crb-2 room 345 · curriculum vitae for academic promotion the...

CURRICULUM VITAE FOR ACADEMIC PROMOTION

The Johns Hopkins University School of Medicine

July 21, 2017 Robert A. Anders, M.D., Ph.D. Date DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments: University: Associate Professor of Pathology Hospital: Pathologist, The Johns Hopkins Hospital

Personal Data:

Business Address: 1550 Orleans Street CRB-2 Room 345 Baltimore, MD 21231

Education and Training:

1991 B.S. University of Illinois Chicago Biochemistry 1998 M.D. Mayo Medical School Medicine 1998 Ph.D. Mayo Graduate School Molecular Biology 1998-2002 Resident University of Chicago AP/CP Pathology 2000-2002 Chief Resident University of Chicago AP/CP Pathology 2002-2004 Fellow University of Chicago GI/Liver Pathology 2002-2004 Postdoctoral Fellow University of Chicago Immunology

Professional Experience:

2004-2005 Instructor, Department of Pathology University of Chicago Hospitals, Chicago IL

2005-2010 Assistant Professor, Department of Pathology

Johns Hopkins Hospital, Baltimore MD

2010-present Associate Professor, Department of Pathology

Johns Hopkins Hospital, Baltimore MD

RESEARCH ACTIVITIES

Publications: Peer-reviewed scientific articles 1. Rabito SF, Anders RA, Soden W, Skidgel RA. Carboxypeptidase N concentration during cardiopulmonary bypass in humans. Can J Anesth. 1992; 39:54-9.

mailto:[email protected]

Robert A. Anders, M.D., Ph.D. July 3, 2014 page 2 of 36

2. Eblen ST, Fautsch MP, Anders RA, Leof EB. Conditional binding to and cell cycle-regulated inhibition of cyclin-dependant kinase complexes by p27Kip1. Cell Growth & Differentiation. 1995 Aug;6(8):915-25. PMID: 8547220 3. Fautsch MP, Eblen ST, Anders RA, Burnette RJ, Leof EB. Differential regulation of p34cdc2 and p33cdc2 by transforming growth factor-beta 1 in murine mammary epithelial cells. Journal of Cellular Biochemistry. 1995; Aug;58(4):517-26. PMID: 7593274

4. Anders RA, Gustafson M, Edens M, Limper AH, Leof EB. Pneumocystis carinii modulates cyclin-dependant kinase activity in a lung epithelial cell line. The Journal of Eukaryotic Microbiology. 1996 Sept-Oct;43(5):13S. PMID: 8822821

5. Anders RA, Leof EB. Chimeric granulocyte/macrophage colony-stimulating factor/transforming growth factor-beta (TGF-beta) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-beta signaling. The Journal of Biological Chemistry. 1996 Sep 6;271(36):21758-66. PMID: 8702972

6. Limper AH, Thomas CF Jr, Anders RA, Leof EB. Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia. The Journal of Laboratory and Clinical Medicine. 1997 Aug;130(2):132-8. PMID: 9280140

7. Anders RA, Arline SL, Doré JJ, Leof EB. Distinct endocytic responses of heteromeric and homomeric transforming growth factor beta receptors. Molecular Biology of the Cell. 1997 Nov;8(11):2133-43. PMID: 9362058. PMCID: PMC25697

8. Limper AH, Edens M, Anders RA, Leof EB. Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. The Journal of Clinical Investigation. 1998 Mar 1;101(5):1148-55. PMID: 9486986. PMCID: PMC508667 9. Thomas CF, Anders RA, Gustafson MP, Leof EB, Limper AH. Pneumocystis carinii contains a functional cell-division-cycle Cdc2 homologue. American Journal of Respiratory Cell and Molecular Biology. 1998 Mar;18(3):297-306. PMID: 9490647 10. Anders RA, Doré JJ Jr, Arline SL, Garamszegi N, Leof EB. Differential requirement for type I and type II transforming growth factor beta receptor kinase activity in ligand-mediated receptor endocytosis. The Journal of Biological Chemistry. 1998 Sep 4;273(36):23118-25. PMID: 9722540 11. Anders RA, Yerian LM, Tretiakova M, Davison JM, Quigg RJ, Domer PH, Hoberg J, Hart J. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. The American Journal of Pathology. 2003 Mar;162(3):991-1000. PMID: 12598331. PMCID: PMC1868091

12. Yerian LM, Anders RA, Tretiakova M, Hart J. Caveolin and thrombospondin expression during hepatocellular carcinogenesis. The American Journal of Surgical Pathology. 2004 Mar;28(3):357-64. PMID: 15104298

13. Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, Karaliukas R, Kang HS, Turner JR,


Fu YX. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. The Journal of Clinical Investigation. 2004 Mar;113(6):826-35. PMID: 15067315. PMCID: PMC362120 14. Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. The Journal of Clinical Investigation. 2004 Mar;113(5):694-700. PMID: 14991067. PMCID: PMC351315

15. Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Lui X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. The Journal of Clinical Investigation. 2005 Mar;115(3):711-7. PMID: 15696194. PMCID: PMC546456

16. Wang J, Anders RA, Wang Y, Turner JR, Abraham C, Pfeffer K, Fu YX. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. Journal of Immunology. 2005 Jun 15;174(12):8173-82. PMID: 15944326

17. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. Journal of Immunology. 2005 Jul 15;175(2):1295-300. PMID: 16002734

18. Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. International Journal of Gastrointestinal Cancer. 2006;37(4):103-9. PMID: 18175224

19. Tong J, Bandulwala HS, Clay BS, Anders RA, Shilling RA, Balachandran DD, Chen B, Weinstock JV, Solway J, Hamman KJ, Sperling AI. Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. The Journal of Experimental Medicine. 2006 May 15;203(5):1173-84. Epub 2006 Apr 17. PMID: 16618792. PMCID: PMC2121201 20. Wisell J, Boitnott J, Haas M, Anders RA, Hart J, Lewis JT, Abraham SC, Torbenson M. Glycogen pseudoground glass change in hepatocytes. The American Journal of Surgical Pathology. 2006 Sep;30(9):1085-90. PMID: 16931952

21. Arruda MS, He DS, Friedman P, Nakagawa H, Bruce C, Azegami K, Anders RA, Kozel P, Chiavetta A, Marad P, MacAdam D, Jackman W, Wilber DJ. A novel mesh electrode catheter for mapping and radiofrequency delivery at the left atrium-pulmonary vein junction: a single-catheter approach to pulmonary vein antrum isolation. J Cardiovasc Electrophysiol. 2007;18(2):206-11.

22. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Annals of Surgery. 2007 Mar;245(3):435-42. PMID: 17435551. PMCID: PMC1877015

23. Xu Y, Flies AS, Flies DB, Zhu G, Anand S, Flies SJ, Xu H, Anders RA, Hancock WW,

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16931952&query_hl=30&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Flies+AS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Flies+DB%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Zhu+G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Anand+S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Flies+SJ%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Xu+H%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Anders+RA%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Hancock+WW%22%5BAuthor%5D


Chen L, Tamada K. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood. 2007 May 1;109(9):4097-104. Epub 2006 Dec 19. PMID: 17179227. PMCID: PMC1874563

24. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007 Sep 21;130(6):1120-33. PMID: 17889654. PMCID: PMC2666353

25. Grosso JF, Kelleher CC Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders RA, Netto G, Getner D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. The Journal of Clinical Investigation. 2007 Nov;117(11):3383-92. PMID: 17932562. PMCID: PMC2000807 26. Collins S. Lutz MA, Zarek PE, Anders RA, Kersh GJ, Powell JD. Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. European Journal of Immunology. 2008 Feb;38(2):528-36. PMID: 18203138. PMCID: PMC3598016 27. Papa S, Zazzeroni F, Fu XY, Bubici C, Alvarez K, Dean K, Christiansen PA, Anders RA, Franzoso G. Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. The Journal of Clinical Investigation. 2008 May;118(5):1911-23. PMID: 18382767. PMCID: PMC2276398 28. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-associated protein, in common solid tumors. Human Pathology. 2008 Nov;39(11):1582-9. Epub 2008 Aug 13. PMID: 18703216. PMCID: PMC2720436 29. Tumanov AV, Koroleva EP, Christiansen PA, Khan MA, Ruddy MJ, Burnette B, Papa S, Franzoso G, Nedospasov SA, Fu YX, Anders RA. T cell-derived lymphotoxin regulates liver regeneration. Gastroenterology. 2009 Feb;136(2):694-704. Epub 2008 Sept 18. PMID: 18952083. PMCID: PMC3060763 30. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, Eshleman JR. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Molecular Cancer Research. 2009 Feb;7(2):230-6. Epub 2009 Feb 10. PMID: 19208745. PMCID: PMC2708114 31. Daniels JA, Torbenson M, Anders RA, Boitnott JK. Immunostaining of plasma cells in primary biliary cirrhosis. American Journal of Clinical Pathology. 2009 Feb;131(2):243-9. PMID: 19141384 32. Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. Journal of Cellular Physiology. 2009 Apr;219(1):209-18. PMID: 19097035 33. Daniels JA, Torbenson M, Vivekanandan P, Anders RA, Boitnott JK. Hepatitis in

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Chen+L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Tamada+K%22%5BAuthor%5D


common variable immunodeficiency. Human Pathology. 2009 Apr;40(4):484-8. Epub 2008 Dec 11. PMID: 19084266 34. Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, Anders RA, Rother RP, Brodsky RA, Cameron AM. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transplantation. 2009 May;15(5):540-3. PMID: 19399743 35. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders RA, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Research. 2009 May 15;69(10):4309-18. Epub 2009 May 12. PMID: 19435909. PMCID: PMC3084614 36. Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, Hruban RH, Anders RA. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery. 2009 Aug;146(2):250-7. PMID: 19628081. PMCID: PMC3402913

37. Wheeler YY, Wheeler GL, Diaz-Arias AA, Anders RA. Metastatic renal cell carcinoma within a hepati c focal nodular hyperplasia: a case report and review of the literature.Int J Clin Exp Pathol. 2009;2(2):190-3. Epub 2008 Jun 9. PMID:19079655 38. Yen HR, Harris TJ, Wada S, Grosso JF, Getnet D, Goldberg MV, Liang KL, Bruno TC, Pyle KJ, Chan SL, Anders RA, Trimble CL, Adler AJ, Lin TY, Pardoll DM, Huang CT, Drake CG. Tc17 CD8 T cells: functional plasticity and subset diversity. Journal of Immunology. 2009 Dec 1;183(11):7161-8. Epub 2009 Nov 16. PMID: 19917680. PMCID: PMC3082359 39. Karp JK, Akpek EK, Anders RA. Autoimmune hepatitis in patients with primary Sjögren's syndrome: a series of two-hundred and two patients. International Journal of Clinical and Experimental Pathology. 2010 Mar 25;3(6):582-6. PMID: 20661405. PMCID: PMC2907119 40.Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology. 2010 May;56(6):683-93. PMID: 20546333 41. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders RA, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology. 2010 Jul 1;28(19):3167-75. Epub 2010 Jun 1. PMID: 20516446 42. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate

http://www.ncbi.nlm.nih.gov/pubmed/20661405



tissue homeostasis in mammals. Developmental Cell. 2010 Jul 20;19(1):27-38. PMID: 20643348. PMCID: PMC2925178 43.Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. American Journal of Surgical Pathology. 2010 Aug;34(8):1147-54. PMID: 20661013. PMCID: PMC3160135 44. Nathan H, Shore AD, Anders RA, Wick EC, Gearhart SL, Pawlik TM. Variation in lymph node assessment after colon cancer resection: patient, surgeon, pathologist, or hospital? Journal of Gastrointestinal Surgery. 2011 Mar;15(3):471-9. Epub 2010 Dec 21. PMID: 21174232. PMCID: PMC3568530 45.Omenetti A, Bass LM, Anders RA, Clemente MG, Francis H, Guy CD, McCall S, Choi SS, Alpini G, Schwarz KB, Diehl AM, Whitington PF. Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia. Hepatology. 2011 Apr;53(4):1246-58. PMID: 21480329. PMCID: PMC3074103 46. Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei PB, Van Eyk JE, Maitra A, Laheru D, Jaffee EM. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One. 2011 Apr 29;6(4). PMID: 21572519. PMCID: PMC3084841 47. Singhi AD, Adsay NV, Swierczynski SL, Torbenson M, Anders RA, Hruban RH, Argani P. Hyperplastic Luschka ducts: a mimic of adenocarcinoma in the gallbladder fossa. The American Journal of Surgical Pathology. 2011 Jun;35(6):883-90. PMID: 21566517. PMCID: PMC3568524

48. Kamel, SI, de Jong MC, Schulick RD, Diaz-Montes TP, Wolfgang CL, Hirose K, Edil BH, Choti MA, Anders RA, Pawlik TM. The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma. World Journal of Surgery. 2011 Jun;35(6):1345-54. PMID: 21452068. PMCID: PMC3568526 49. De Jong MC, Hong SM, Augustine MM, Goggins MG, Wolfgang CL, Hirose K, Schulick RD, Choti MA, Anders RA, Pawlik TM. Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Archives of Surgery. 2011 Jun;146(6):697-703. PMID: 21690446. PMCID: PMC3308171 50. Mayo SC, Shore AD, Nathan H, Edil BH, Hirose K, Anders RA, Wolfgang CL, Schulick RD, Choti MA, Pawlik TM. Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford). 2011 Jul;13(7):473-82. Epub 2011 May 18. PMID: 21689231. PMCID: PMC3133714 51.Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. Journal of Neuropathology and Experimental Neurology. 2011 Jul;70(7):568-77. PMID: 21666501. PMCID: PMC3130608




52. Mayo SC, Heckman JE, Shore AD, Nathan H, Parikh AA, Bridges JF, Anders RA, Anaya DA, Becker NS, Pawlik TM. Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis. Surgery. 2011 Aug;150(2):204-16. PMID: 21801959. PMCID: PMC3568532 53. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Zhou S, Vogelstein B, Hruban RH, Papadopoulos N, Cai J, Torbenson MS, Kinzler KW. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics. 2011 Aug 7;43(9):828-9. PMID: 21822264. PMCID: PMC3163746 54. Bisht S, Khan MA, Bekhit M, Bai H, Cornish T, Mizuma M, Rudek MA, Zhao M, Maitra A, Ray B, Lahiri D, Anders RA. A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Laboratory Investigation. 2011 Sep;91(9):1383-95. Epub 2011 Jun 20. PMID: 21691262. PMCID: PMC3345948 55. Lam-Himlin D, Tsiatis AC, Montgomery E, Pai RK, Brown JA, Razavi M, Lamps L, Eshleman JR, Bhagavan B, Anders RA. Sarcina organisms in the gastrointestinal tract: a clinicopathologic and molecular study. The American Journal of Surgical Pathology. 2011 Nov;35(11):1700-5. PMID: 21997690. PMCID: PMC3193598 56. Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, Yang XR, Zhu QF, Sun YF, Maitra A, Fan J, Anders RA. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clinical Cancer Research. 2012 Mar 1;18(5):1291-302. Epub 2011 Aug 25. PMID: 21868763. PMCID: PMC3233659 57.Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Translational Medicine. 2012 Mar 28;4(127):127ra37. PMID: 22461641. PMCID: PMC3568523 58. Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, Xu H, Dhall D, Wang HL. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Human Pathology. 2012 May;43(5):695-701. Epub 2011 Sep 19. PMID: 21937079. PMCID: PMC3568522 59. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & Development. 2012 Jun 15;26(12):1300-5. Epub 2012 Jun 7. PMID: 22677547. PMCID: PMC3387657 60.Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu



http://www.ncbi.nlm.nih.gov/pubmed?term=Topalian%20SL%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Hodi%20FS%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Brahmer%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Gettinger%20SN%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=McDermott%20DF%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Powderly%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Powderly%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Carvajal%20RD%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Sosman%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Atkins%20MB%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Leming%20PD%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Spigel%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Antonia%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Horn%20L%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Drake%20CG%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Pardoll%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20L%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Sharfman%20WH%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Anders%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Taube%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=McMiller%20TL%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Xu%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22658127


H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. 2012 Jun 28;366(26):2443-54. Epub 2012 Jun 2. PMID: 22658127. PMCID: PMC3544539

61.Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 62. Bai H, Zhang N, Xu Y, Chen Q, Khan M, Potter JJ, Nayar SK, Cornish T, Alpini G, Bronk S, Pan D, Anders RA. Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology. 2012 Sep;56(3):1097-107. Epub 2012 Aug 8. PMID: 22886419. PMCID: PMC3431197 63. Bai H, Gayyed MF, Lam-Himlin DM, Klein AP, Nayar SK, Xu Y, Khan M, Argani P, Pan D, Anders RA. Expression of Yes-associated protein modulates Survivin expression in primary liver malignancies. Human Pathology. 2012 Sep;43(9):1376-85. Epub 2012 Mar 19. PMID: 22436626. PMCID: PMC3384990 64. Hourigan SK, Anders RA, Mitchell SE, Schwarz KB, Lau H, Karnsakul W. Chronic diarrhea, ascites, and protein-losing enteropathy in an infant with hepatic venous outflow obstruction after liver transplantation. Pediatric Transplantation. 2012 Nov;16(7):E328-31. Epub 2012 Apr 10. PMID: 22489846. PMCID: PMC3568531 65. Wolfe JL, Anders RA, Reddoch S, Schwarz KB, Savage WJ. Longitudinal changes in liver fibrosis in children with sickle cell disease undergoing chronic transfusion therapy. Acta Gastro-enterologica Belgica. 2012 Dec;75(4):419-24. PMID: 23402085 66. Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG 3rd, Gamblin TC, Pawlik TM. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Annals of Surgical Oncology. 2012 Dec;19(13):4036-42. Epub 2012 Sep 13. PMID: 22972507. PMCID: PMC3568525 67. Bigelow E, Bever KM, Xu H, Yager A, Wu A, Taube J, Chen L, Jaffee EM, Anders RA, Zheng L. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. Journal of Visualized Experiments. 2013 Jan 3;(71). PMID: 23328703. PMCID: PMC3582653 68. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clinical Cancer Research. 2013 Jan 15;19(2):462-8. Epub: 2012 Nov 20. PMID: 23169436. PMCID: PMC3548952

http://www.ncbi.nlm.nih.gov/pubmed?term=Xu%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Korman%20AJ%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Jure-Kunkel%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Agrawal%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=McDonald%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Kollia%20GD%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Gupta%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Wigginton%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Wigginton%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=22658127

http://www.ncbi.nlm.nih.gov/pubmed?term=Sznol%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22658127













69. Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, Nayar SK, Devbhandari RP, He YZ, Zhu QF, Sun YF, Hu B, Khan M, Anders RA, Fan J. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology. 2013 Mar;57(3):1088-97. Epub 2013 Feb 7. PMID: 23212661. PMCID: PMC3594482 70. Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L, Geller DA, Sempoux C, Herlea V, Popescu I, Anders RA, Rubbia-Brandt L, Gigot JF, Mentha G, Pawlik TM. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013 Apr;17(4):748-55. Epub 2013 Jan 25. Erratum in: Journal of Gastrointestinal Surgery. 2013 Nov;17(11):2031. PMID: 23355033. PMCID: PMC4007003 71. Zhang J, Mavros MN, Cosgrove D, Hirose K, Herman JM, Smallwood-Massey S, Kamel I, Gurakar A, Anders RA, Cameron A, Geschwind JF, Pawlik TM. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Current Oncology. 2013 Apr;20(2):e123-31. PMID: 23559879. PMCID: PMC3615863 72. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube JM. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunology Research. 2013 Jul;1(1):54-63. PMID: 24416729. PMCID: PMC3885978 73. Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders RA, Cameron A, Pawlik TM. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. Journal of Gastrointestinal Surgery. 2013 Sep;17(9):1600-8. Epub 2013 Jun 19. PMID: 23780638. PMCID: PMC4002207 74. Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, Beierl K, Eshleman JR, Lin MT, Pawlik TM, Anders RA. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Human Pathology. 2013 Dec;44(12):2768-73. Epub 2013 Oct 15. PMID: 24139215. PMCID: PMC3838441 75. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics. 2013 Dec;45(12):1470-3. Epub 2013 Nov 3. PMID: 24185509. PMCID: PMC4013720

76. Guo X, Qiu J, Tu T, Yang X, Deng L, Anders RA, Zhou L, Fu YX. Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity. 2014 Jan 16;40(1):25-39. Epub 2014 Jan 9. PMID:















24412612. PMCID: PMC3919552 77. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, Kamel I, Anders RA, Pawlik TM. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. Journal of the American College of Surgeons. 2014 Feb;218(2):196-205. Epub 2013 Oct 24. PMID: 24315886 78. Gurda GT, Zhu Q, Bai H, Pan D, Schwarz KB, Anders RA. The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Human Pathology. 2014 May;45(5):1057-64. Epub 2014 Jan 23. PMID: 24746211. PMCID: PMC4151519 79. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, Laheru D, Wolfgang CL, Wang J, Hruban RH, Anders RA, Jaffee EM, Zheng L. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunology Research. 2014 Jul;2(7):616-31. Epub 2014 Jun 18. PMID: 24942756. PMCID: PMC4082460 80. Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer. 2014 Oct 1;120(19):3058-65. Epub 2014 Jun 10. PMID: 24917245. PMCID: PMC4316688 81.Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical Cancer Research. 2014 Oct 1;20(19):5064-74. Epub 2014 Apr 8. PMID: 24714771. PMCID: PMC4185001 82. Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Annals of Surgical Oncology. 2014 Nov;21(12):3827-34. Epub 2014 Jun 3. PMID: 24889489. PMCID: PMC4324507 83. Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, Drake CG. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One. 2014 Nov 5;9(11). PMID: 25372844. PMCID: PMC4220939 84. Spolverato G, Anders RA, Kamel I, Pawlik TM. Segmental atrophy of the liver: an uncommon and often unrecognized pseudotumor. Digestive Diseases and Sciences. 2014 Dec;59(12):3122-5. Epub 2014 Jun 7. PMID: 24906695. PMCID: PMC4332788 85. Iordanskaia T, Koeck E, Rossi C, Mohan P, Schwarz K, Anders RA, Nadler EP. Integrin β-8, but not β-5 or -6, protein expression is increased in livers of children with biliary atresia. Journal of Pediatric Gastroenterology and Nutrition. 2014 Dec;59(6):679-83. PMID: 25079481
















86. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discovery. 2015 Jan;5(1):43-51. Epub 2014 Oct 30. PMID: 25358689. PMCID: PMC4293246 87. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. Journal of Immunotherapy. 2015 Jan;38(1):1-11. PMID: 25415283. PMCID: PMC4258151 88. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. Cancer Discov. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.2015 Jan;5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863. Epub 2014 Oct 30.PMID:25358689 89. Rodić N, Anders RA, Eshleman JR, Lin MT, Xu H, Kim JH, Beierl K, Chen S, Luber BS, Wang H, Topalian SL, Pardoll DM, Taube JM. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunology Research. 2015 Feb;3(2):110-5. Epub 2014 Nov 4. PMID: 25370533. PMCID: PMC4324161 90. Surcel A, Ng WP, West-Foyle H, Zhu Q, Ren Y, Avery LB, Krenc AK, Meyers DJ, Rock RS, Anders RA, Freel Meyers CL, Robinson DN. Pharmacological activation of myosin II paralogs to correct cell mechanics defects. Proceedings of the National Academy of Sci ences of the United States of America. 2015 Feb 3;112(5):1428-33. Epub 2015 Jan 20. PMID: 25605895. PMCID: PMC4321244 91. Faraj SF, Munari E, Guner G, Taube J, Anders RA, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C, Netto GJ. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015 Mar;85(3):703. PMID: 25733301

92. Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB (Oxford). 2015 Apr;17(4):292-8. Epub 2014 Sep 23. PMID: 25250696. PMCID: PMC4368391 93.Spolverato G, Bhaijee F, Anders RA, Salley K, Parambi J, Brown T, Pawlik TM. Total pancreatectomy for the management of refractory post-gastric bypass hypoglycemia. Digestive Diseases and Sciences. 2015 May;60(5):1505-9. Epub 2014 Oct 26. PMID: 25344909

94. Nguyen Q, Anders RA, Alpini G, Bai H. Yes-associated protein in the liver: Regulation of hepatic development, repair, cell fate determination and tumorigenesis. Digestive and








liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015 May 22. PMID: 26093945 95. Chen Q, Zhang N, Xie R, Wang W, Cai J, Choi KS, David KK, Huang B, Yabuta N, Nojima H, Anders RA, Pan D. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes & development. 2015 Jun 15;29(12):1285-97. PMID: 26109051. PMCID: PMC4495399 96. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine. 2015 Jun 25;372(26):2509-20. Epub 2015 May 30. PMID: 26028255. PMCID: PMC4481136 97. Cai J, Maitra A, Anders RA, Taketo MM, Pan D. Genes Dev. β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis.2015 Jul 15;29(14):1493-506. doi: 10.1101/gad.264515.115. Epub 2015 Jul 20.PMID:26193883 98.Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, Anders RA, Iacobuzio-Donahue CA, Hajjar KA, Maitra A, Jaffee EM, Zheng L. Sci Signal. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. 2015 Aug 4;8(388):ra77. doi: 10.1126/scisignal.aaa5823. PMID:26243191 99.Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, Del Rio A, D'Santos C, Williams R, Chokshi S, Anders RA, Bubici C, Papa S. Nat Commun.PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. 2015 Aug 10;6:7882. doi: 10.1038/ncomms8882.PMID:26258887 100. Bhaijee F, Anders RA,JAMAOncol.2015Nov12:12.doi:10.1001/jamaoncol.2015.3782. [Epub ahead of print] No abstract available. PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence? PMID:26561922 102. Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, Maitra A, Anders RA, Xu Y. Biochem Biophys Res Commun. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. 2015 Dec 25;468(4):525-32. doi: 10.1016/j.bbrc.2015.10.031. Epub 2015 Oct 19. PMID:26482853 103. Doucet-O'Hare TT, Rodić N, Sharma R, Darbari I, Abril G, Choi JA, Young Ahn J, Cheng Y, Anders RA, Burns KH, Meltzer SJ, Kazazian HH Jr. Proc Natl Acad Sci U S A.


LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma. 2015 Sep 1;112(35):E4894-900. doi: 10.1073/pnas.1502474112. Epub 2015 Aug 17. PMID:26283398 104. Ewing AD, Gacita A, Wood LD, Ma F, Xing D, Kim MS, Manda SS, Abril G, Pereira G, Makohon-Moore A, Looijenga LH, Gillis AJ, Hruban RH, Anders RA, Romans KE, Pandey A, Iacobuzio-Donahue CA, Vogelstein B, Kinzler KW, Kazazian HH Jr, Solyom S. Genome Res. Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. 2015 Oct;25(10):1536-45. doi: 10.1101/gr.196238.115. Epub 2015 Aug 10. PMID:26260970 105. Clemente MG, Patton JT, Anders RA, Yolken RH, Schwarz KB. Biomed Res Int. Rotavirus Infects Human Biliary Epithelial Cells and Stimulates Secretion of Cytokines IL-6 and IL-8 via MAPK Pathway. 2015;2015:697238. doi: 10.1155/2015/697238. Epub 2015 Jul 13. PMID: 26247025 106. Gorgy AI, Jonassaint NL, Stanley SE, Koteish A, DeZern AE, Walter JE, Sopha SC, Hamilton JP, Hoover-Fong J, Chen AR, Anders RA, Kamel IR, Armanios M. Chest. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. 2015 Oct;148(4):1019-26. doi: 10.1378/chest.15-0825. PMID:26158642 107. Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, Maitra A, Anders RA, Xu Y. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochem Biophys Res Commun. 2015 Dec 25;468(4):525-32. doi: 10.1016/j.bbrc.2015.10.031. Epub 2015 Oct 19. PMID:26482853 108. Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Ann Surg. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. 2016 Jan 7. [Epub ahead of print] PMID:26756760 Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders RA, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer. JAMA Oncol. Published online March 09, 2017. doi:10.1001/jamaoncol.2017.0013. PMID: 28278348

Surcel A, Schiffhauer E,Thomas D, Zhu Q, Anders RA, Robinson D. Dictyostelium Mechanics Accurately Identifies New Targetable Drug Space for Pancreatic Cancer Delineated by Myosin IIS, Filamins, and Alpha-Actinins, Collectively Comprimising the Mechanobiome. Elsevier. 2017 Feb 3:112 (3):338a.

Xing, D, Luan, L, Zhu, Q, Gani, F, Pawlik, T, Taube, J M, Anders, R A PD-L1 and LAG3 Expression in Hepatocellular Carcinoma Associated with HCV and Steatohepatitis. In Laboratory Investigation. 2017 Feb:40 (12): 1601-1615(15).

https://www.ncbi.nlm.nih.gov/pubmed/26482853



http://www.cell.com/biophysj/abstract/S0006-3495(16)32859-4





David R, Gang H,Taube J M, Eunhee S Y, Bridge J A, Flieder D B, Homer R, West H, Wu W W, Roden A C, Fujimoto J, Yu H, Anders R A, Kowalewski A, Rivard C, Rehman J, Hirsch F, Wistuba I I. ORAL01. 01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry. Journal of Thoracic Oncology. 2016 Nov: 11 (11): S249. DOI: 10.1016/j.jtho.2016.09.006. PMID: 27969440

Ascierto M L, McMiller T L, Berger A E, Danilova L, Anders R A, Netto G J, Xu H, Pritchard T S, Fan J, Cheadle C, Cope L, Drake C G, Pardoll D M, Taube J M, Topalian S L. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research. 2016 Sep. 2: 4 (9): 726-733. PMID: 27491898 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.Gut. 2017 May;66(5):794-801. doi: 10.1136/gutjnl-2015-310839. Epub 2016 Jan 22. PMID:26801886 Bhaijee F, Anders RA. PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the same as Proof of Absence? JAMAOncol.2016Jan;2(1):545.doi:0.1001/jamaoncol.2015.3782. No abstract available. PMID:26561922 Xiao Q, Zhou D, Rucki AA, Williams J, Zhou J, Mo G, Murphy A, Fujiwara K, Kleponis J, Salman B, Wolfgang CL, Anders RA, Zheng S, Jaffee EM, Zheng L. Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Cancer Res. 2016 Sep 15;76(18):5395-404. doi: 10.1158/0008-5472.CAN-15-3264. Epub 2016 Aug 5. PMID:27496707 Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunol Res. 2016 Sep 2;4(9):726-33. doi: 10.1158/2326-6066.CIR-16-0072. Epub 2016 Aug 4. PMID:27491898 Doucet-O'Hare TT, Sharma R, Rodić N, Anders RA, Burns KH, Kazazian HH Jr. Hum Mutat. Somatically Acquired LINE-1 Insertions in Normal Esophagus Undergo Clonal Expansion in Esophageal Squamous Cell Carcinoma. 2016 Sep;37(9):942-54. doi: 10.1002/humu.23027. Epub 2016 Jul 13. PMID:27319353 Bai H, Zhu Q, Surcel A, Luo T, Ren Y, Guan B, Liu Y, Wu N, Joseph NE, Wang TL, Zhang N, Pan D, Alpini G, Robinson DN, Anders RA. Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization. Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G396-411. doi: 10.1152/ajpgi.00027.2016. Epub 2016 May 26. PMID:27229120

http://www.jto.org/article/S1556-0864(16)30955-8/abstract

http://www.jto.org/article/S1556-0864(16)30955-8/abstract

http://cancerimmunolres.aacrjournals.org/content/4/9/726.short

http://cancerimmunolres.aacrjournals.org/content/4/9/726.short
















Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD. Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway. J Transl Med. 2016 Oct 19;14(1):295. PMID:27756323 Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. Epub 2016 Nov 11. PMID:27837027 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755. PMID:27806233 Jakhete N, Saberi B, Jonassaint NL, Cosar AM, Luu H, Kim A, Anders RA, Philosophe B, Cameron AM, Gurakar A. Microvascular Invasion in Hepatocellular Carcinoma and Liver Transplant. Exp Clin Transplant. 2016 Nov;14(Suppl 3):14-18. PMID:27805503 Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA, Magid MS, Melin-Aldana H, Ranganathan S, Shehata BM, Wang LL, White FV, Chen Z, Spino C; Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study. Childhood Liver Disease Research Network (ChiLDReN).Am J Surg Pathol. 2016 Dec;40(12):1601-1615. PMID:27776008 Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Epub 2016 Feb 3. Erratum in: Cancer Immunol Res. 2016 May;4(5):472. PMID:26842750 Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT. Ganetespib radiosensitization for liver cancer therapy.Cancer Biol Ther. 2016 Apr 2;17(4):457-66. doi: 10.1080/15384047.2016.1156258. PMID:26980196 Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer. 2016 May;16(5):275-87. doi: 10.1038/nrc.2016.36. Epub 2016 Apr 15. Review. PMID:27079802




















Arifin DR, Valdeig S, Anders RA, Bulte JW, Weiss CR. Magnetoencapsulated human islets xenotransplanted into swine: a comparison of different transplantation sites. Xenotransplantation. 2016 May;23(3):211-21. doi: 10.1111/xen.12235. Epub 2016 May 26. PMID:27225644

Gani F, Nagarajan N, Kim Y, Zhu Q, Luan L, Bhaijjee F, Anders RA, Pawlik TM. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.Ann Surg Oncol. 2016 Aug;23(8):2610-7. doi: .1245/s10434-016-5101-y. Epub 2016 Mar 24. PMID:27012989 Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio, Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg. 2016 Dec;264(6):1073-1081. PMID:26756760 Luchini C, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A, Nottegar A, Veronese N, He J, Weiss MJ, Capelli P, Scarpa A, Argani P, Kapur P, Wood LD. PBRM1 loss is a late event during the development of cholangiocarcinoma. Histopathology. 2017 Apr 10. doi: 10.1111/his.13234. PMID:28394406 Sunshine JC, Nguyen P, Kaunitz G, Cottrell T, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KR, Cornish TC, Lipson EJ, Anders RA, Taube J. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clin Cancer Res. 2017 Apr 20. pii: clincanres.1821.2016. doi: 10.1158/1078-0432.CCR-16-1821. PMID:28428193

Reviews 1. Anders RA, Kamel IR. Biopsy considerations in the diagnosis of hepatic masses. Clinical Gastroenterology and Hepatology. 2007 May;5(5):541-4. PMID: 17478344 2. Anders RA, Montgomery EM, Maitra A. Johns Hopkins course: 8th annual Current Topics in Gastrointestinal and Liver Pathology. Expert Review of Gastroenterology & Hepatology. 2009 Feb;3(1):33-7. PMID: 19210111 3. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF, Pawlik TM. Intrahepatic cholangiocarcinoma: management options and emerging therapies. Journal of the American College of Surgeons. 2013 Oct;217(4):736-750. Epub 2013 Jul 24. PMID: 23890842 4. Soares KC, Arnaoutakis DJ, Kamel I, Anders R, Adams RB, Bauer TW, Pawlik TM. Cystic neoplasms of the liver: biliary cystadenoma and cystadenocarcinoma. Journal of the American College Surgeons. 2014 Jan;218(1):119-28. Epub 2013 Sep 14. PMID: 24045144. PMCID: PMC4106371













4. Soares KC, Arnaoutakis DJ, Kamel I, Rastegar N, Anders R, Maithel S, Pawlik TM. Choledochal cysts: presentation, clinical differentiation, and management. Journal of the American College of Surgeons. 2014 Dec;219(6):1167-80. Epub 2014 Jun 27. PMID: 25442379. PMCID: PMC4332770 5. Margonis GA, Ejaz A, Spolverato G, Rastegar N, Anders R, Kamel IR, Pawlik TM. Benign Solid Tumors of the Liver: Management in the Modern Era. Journal of Gastrointestinal Surgery. 2015 Jan 6. PMID: 25560181 Inventions, Patents, Copyrights N/A

Extramural Funding Current ACTIVE 07/01/2016-06/30/2021 R01CA203891 NIH/NCI $228,750 PI:Housseau Role: Co-Investigator; 2% effort Notes: Correlates of antitumor immunity in colorectal cancers and anti-PD1 therapy The major goal of this project is to define the correlates of the immune response to neoantigens in CRC and will test the hypothesis that such biomarkers delineate MSS metastatic CRC patients who could benefit from anti-PD1 therapy. 1/1/2016 – 12/31/2020 Bloomberg Family Foundation Bloomberg Kimmel Institute for Cancer Immunotherapy $9,000,000 PI: Taube/Anders Role: Co-Investigator; 10% effort Notes: The goal of the institute is to help develop, within 10 years, immunotherapies that can place 50% of people with inoperable cancer into lifelong remission. Role: Co-investigator; Co-Director of Tumor Microenvironment Core 08/05/2016-08/05/2018 90070416 Five Prime Therapeutics Tumor Environment $259,759 PI: Anders Role: PI; 2% effort Note: The goal of this study is to review and score the pathology slides of a clinical trial that is combining a novel proprietary antibody with nivolumab. This should increase the ability


of the immune system to recognize and eliminate tumor cells by removing two key negative regulatory pathways. 07/01/2016-12/31/18 BMS BMS $524,514 PI: Topalian Role: Co-Investigator; 3% effort Note: Analysis of PD-1 blockade in virus-associated cancers on CA209-358 The goal of this project is to characterize changes in the tumor immune microenvironment in pre/post therapy biopsies from patients with advanced virus-associated cancers receiving anti-PD-1 therapy on clinical trial CA209-358, in order to understand response and resistance to therapy. 04/01/2016-03/31/2018 Gateway Grant No. G-16-600 Gateway for Cancer Research $13,138 PI: Zheng Role: Co-Investigator; 5% effort Note: A Ph II study of a GM-CSF secreting allogeneic pancreatic cancer vaccine in combination with PD-1 blockade antibody for the treatment of pts with locally advanced adenocarcinoma of the pancreas.The goal of this project is to characterize the immune microenvironment in pancreatic cancer. 06/15/16-06/04/17 National Comprehensive Cancer Network Pilot NCCN $13,000 PI: Taube Role: Co-Investigator; 2% effort Note: A Multi-Institutional Analysis of Programmed Cell Death Ligand-1 (PD-L1) Expression in Lung Cancer. The goal of this project is to characterize the immune microenvironment in lung cancer. 09/19/12-08/31/17 2P50 CA062924 SPORE in Gastrointestinal Cancer NIH/NCI $78,200 PI: Klein Role: Core Director; effort 17% Note: The goal of Core 2 is to facilitate tissue based studies of SPORE related projects and collaborations by providing pathologic expertise and histologic assessments. 01/03/13-12/31/17 R01CA172380 NIH/NCI


$213,989 PI: Meeker Role: Co-Investigator; effort 6% Note: Determining the roles of ATRX and DAXX abnormalities in cancer telomere biology The overall objectives of this proposal are to elucidate the roles of defective ATRX and DAXX in the ALT phenotype, with an eye towards exploiting these defects for potential therapeutic purposes. 05/01/13-04/30/17 R01 EB017615 NIBIB $208,250 PI: Kraitchman/Weiss Role: Co-Investigator; effort 4% Note: Image-guided Bariatric Arterial Embolization (BAE) for the Treatment of Obesity The prevalence of obesity is increasing in the United States and worldwide with significant negative effects to both health and the economy. This study will evaluate and improve upon a new minimally invasive image-guided therapy for morbid obesity in which specific blood vessels to the stomach are blocked in order to suppress the body's signals for feeling hungry, leading to weight loss. Our goal is to use new catheters, new imaging techniques, and new X-ray visible implantable beads to make the procedure safe, accurate and effective. 05/07/13-05/06/17 Bristol-Myers Squibb Company BMS Resource Model $486,987 PI: Pardoll Role: Co-Investigator; 6% effort Note: The goal of this clinical research network is to conduct immunotherapy trials with the novel agents including anti-CD137 and others, and to collaboratively evaluate pharmacodynamics and potential biomarkers of response. 04/16/14-04/15/17 Lefkofsky Foundation Targeting Mutated Kras $90,909 PI: Jaffee Role: Co-Investigator; 5% effort Note: In this three year study we will test the hypothesis that targeting mutated Kras - the first genetic alteration driving pancreatic cancer initiation - can reverse the local cancer promoting environment to one that prevents cancer development. 07/01/14-12/31/18 Fibrolamellar Cancer Foundation Transplant Immunology Trial $45,494 PI: Fuchs Role: Co-Investigator; 10% effort


Note: The goal of this project is to develop a procedure intended to remove visible tumor and prevent recurrence by getting the body's immune system to fight the cancer with the new bone marrow 08/02/13-05/31/18 R01CA169702 NIH/NCI $207,500 PI: Zheng Role: Co-Investigator; 2% Note: Annexin A2 as a Mediator of Pancreatic Cancer Metastases The goal of this project is elucidation of the complex network of signals that results in cross-talk between the PDA and its microenvironment, and that are mediated through ANXA2 to control PDA invasion and metastasis formation 07/21/2015-06/30/2020 R01CA197296 NIH/NCI $ 336,994 PI: Zheng Role: Co-Investigator; 4% effort Note: Reprogramming the Pancreatic Tumor Microenvironment with Immunotherapy The goal of this proposal is to test an immunotherapy strategy that combines an immune checkpoint inhibitor and a GM-CSF cell based vaccine in patients with resectable pancreatic cancer in both neoadjuvant and adjuvant setting 08/12/2015-06/30/2019 R01DK106972 NIH/NIDDK $310,871 PI: Bulte Role: Co-Investigator; 4% effort Note: Dual-mode MRI for in vivo sensing of microcapsule stability and biocompatibility Our goal is to develop a dual-mode magnetic resonance imaging (MRI) approach that can report on the mechanical stability of implanted capsules over time while simultaneously interrogating the absence or presence of a major host immune response 9/1/15 – 5/31/2020 U01DI082916 NIDDK $451,774 PI: Schwarz, Murray, Rodriguez-Baez Role: Co-Investigator; 2% effort Note: Immunologic and Virologic Correlates of the Age-Related Decrease in HBV DNA in Children. The Hepatitis B Clinical Research Network is the combination of experienced


investigators, understudied populations and two novel approaches to study viral factors that affect HBV viral load, an important determinant of HBV disease. The database study could help validate a promising new biomarker to predict and diagnose HBV liver cancer (HCC). The clinical trial has the possibility of decreasing the high lifetime HCC risk characteristic of immunotolerant youth. 11/21/16-4/20/18 LKR159107 Merck $210,055 PI: Zheng Role: Co-Investigator; 2% effort Note: Comprehensive characterization of immune microenvironment of cholangiocarcinoma to identify targets for immunotherapy The goal is to establish the comprehensive baseline information on the tumor microenvironment of BTCs to assist the correlative immunobiology analysis associated with those clinical trials 07/01/2016-06/30/2018 90069746 ITEOS Therapeutics $156,010 PI: Zheng Role: Co-Investigator; 2% effort Note: Characterization of immune suppressive mechanisms specific for pancreatic ductural adenocarcinoma 07/01/12-06/30/17; SPORE in Gastrointestinal Cancer 2P50 CA062924 NIH/NCI $391,000 TDC PI: Kern Role: PI Core 2; 17% effort Notes: The goal of Core 2 is to facilitate tissue based studies of SPORE related projects and collaborations by providing pathologic expertise and histologic assessments. 01/01/13-12/31/17; Determining the roles of ATRX and DAXX abnormalities in cancer telomere biology R01 CA172380 NIH/NCI $637,100 P.I.: Meeker Role: Co-Investigator; 6% effort starting 4/1/13 Notes: The overall objectives of this proposal are to elucidate the roles of defective ATRX and DAXX in the ALT phenotype, with an eye towards exploiting these defects for potential therapeutic purposes. 05/01/13-04/30/18; Image-guided Bariatric Arterial Embolization (BAE) for the Treatment of Obesity


R01 DK097267 NIBIB $1,062,500 P.I.: Kraitchman/Weiss Role: Co-Investigator; 4% effort Notes: The prevalence of obesity is increasing in the United States and worldwide with significant negative effects to both health and the economy. This study will evaluate and improve upon a new minimally invasive image-guided therapy for morbid obesity in which specific blood vessels to the stomach are blocked in order to suppress the body's signals for feeling hungry, leading to weight loss. Our goal is to use new catheters, new imaging techniques, and new X-ray visible implantable beads to make the procedure safe, accurate and effective. 09/14/11-07/31/16; Cellular Diversity and Clinical Relevance of Stem Cells in Pancreatic Cancer R01 CA150142 NIH/NCI $1,001,470 TDC P.I.: Matsui Role: Co-Investigator, 5% effort Notes: The goal of this project is to define the relationship between distinct cancer stem cell populations in pancreatic cancer. 05/07/13-05/06/17; BMS Resource Model No Identification Number Bristol-Myers Squibb Company 4,869,874 TDC P.I.: Pardoll Role: Co-Investigator; 6% effort Notes: The goal of this clinical research network is to conduct immunotherapy trials with the novel agents including anti-CD137 and others, and to collaboratively evaluate pharmacodynamics and potential biomarkers of response. 06/01/12-05/31/15; Co-encapsulation of Human Mesenchymal Stem Cells and Islet cells for treatment of Type 1 diabetes No Identification Number Technology Development Corporation $541,287 TDC P.I.: Bulte Role: Co-Investigator; 5% effort yrs. 2 and 3 Notes: None. 03/01/13-02/28/16; Immune Checkpoint Blockade and Adoptive Cell Transfer SU2C-AACR-DT10 AACR/MD Anderson Cancer Center $1,404,546 P.I.: Pardoll Role: Co-Investigator; 4% effort


Notes: The major goal of this project is to induce anti-tumor T cell responses either by blocking inhibitory mechanisms intrinsic to T cells thus allowing them to expand, infiltrate and kill cancer cells, or by creating large quantities of such T cells in the laboratory and adoptively transferring these cells back to the patients to obtain the same final effects of anti-tumor T cell responses. 09/30/08-05/31/15; Effect of HBV DNA Methylation and the Mutant 1762T/1764A on Viral Load and HCC. HBV Clinical Research Network. U01DK082916 NIH/NIDDK $742,547 TDC P.I.: Schwarz Role: Co-Investigator; 5% effort Notes: The Hepatitis B Clinical Research Network is the combination of experienced investigators, understudied populations and two novel approaches to study viral factors that affect HBV viral load, an important determinant of HBV disease. The database study could help validate a promising new biomarker to predict and diagnose HBV liver cancer (HCC). The clinical trial has the possibility of decreasing the high lifetime HCC risk characteristic of immunotolerant youth. 04/16/14-04/15/17; Targeting Mutated Kras No Identification Number Lefkofsky Foundation $272,727 TDC P.I.: Jaffee Role: Co-Investigator; 5% effort Goal: In this three year study we will test the hypothesis that targeting mutated Kras - the first genetic alteration driving pancreatic cancer initiation - can reverse the local cancer promoting environment to one that prevents cancer development. Pending 04/01/15-03/31/17; Manipulating Pancreatic Cancer Cell Mechanics to a Non-metastatic State R21 CA194861 NIH/NCI $550,000 TDC P.I. Robinson/Anders Role: Co-PI, 5% effort Notes: The goals of this proposal are to elucidate the mechanical changes associated with pancreatic ductal adenocarcinoma progression and to test 4-HAP in mouse models of metastatic disease. 09/01/2016-08/31/2021 GRANT12082308 NIH/NCI $250,000 PI: Meltzer Role: Co-Investigator; 3% effort Note: Novel Strategy for Early Detection in Barrett's Esophagus


Completed 07/01/04-06/30/09, The Role of Lymphotoxin Receptor in Liver Regeneration K08 DK067187 NIDDK $623,750 TDC PI: Anders Role: PI, 75% effort Notes: The major goal of this project is to define the role of lymphotoxin receptor ligand systems in liver regeneration. 09/24/02-05/31/09, Novel Antigen and T&B Cell Response in Biliary Atresia UO1 DK62503 NIDDK $994,394 TDC PI: Schwartz Role: Co-Investigator, 5% effort Notes: Goals for BARC: define the natural history, histopathology, pathogenesis, and optimum treatment for biliary atresia and other causes of infantile cholestasis (serum direct bilirubin 2 mg/dl or greater in an infant 0 - 180 days of age). Goals for CLIC: define the natural history, histopathology, and optimum treatment for 5 rare liver diseases of childhood: Alagillle Syndrome, alpha-1-antitrypsin deficiency, inborn errors of bile salt synthesis, prolonged familial intrahepatic cholestasis, and mitochondrial hepatopathy. 08/01/11-07/31/12; Validation of PD-1/PD-L1 as tumor biomarkers for response to therapy with BMS-936558 (MDX-1106) and BMS-936559 (MDX-1105) No Identification Number Bristol-Myers Squibb $225,509 P.I.: Topalian Role: Co-Investigator; 10% effort Notes: The goal of this project is to use immunohistochemistry to analyze a large series of pretreatment biopsy samples from cancer patients treated with PD-1/PD-L1 blockade, to determine if expression of PD-1/PD-L1 correlate with clinical outcomes. 06/10/08-05/31/13, The Role of Hippo Pathway in Liver Regeneration R01 DK081417 NIDDK $1,062,500 TDC PI: Anders Role: PI, 18% effort Notes: The long range goal is to define the cellular mechanisms underlying liver regeneration in health and disease and to apply these findings to developing improved therapies for liver disease by defining the regulatory mechanism of the tumor suppressor pathway on hepatocyte division, defining the role of tumor suppressor in controlling hepatocyte apoptosis and defining the interaction of the tumor suppressor pathway and a growth factor pathway in controlling liver size.


09/24/02-05/31/14; The Johns Hopkins Pediatric Liver Center ChiLDREN Grant UO1 DK62503 NIDDK $2,483,664 TDC P.I.: Schwarz Role: Co-Investigator, 5% effort Notes: The goal of this project is to devote the resources of the Johns Hopkins Pediatric Liver Center to continue participation in BARC and CLiC, expand the ongoing study of the role of rotavirus in Human Biliary Atresia, continue participation in the prospective longitudinal study of cystic fibrosis liver disease, continue to provide training opportunities for investigators in pediatric liver disease. 02/13/13-02/12/14; Why do some PD-L1+ tumors not respond to anti-PD-1 therapy? No Identification Number Bristol-Meyers Squibb $80,000 P.I.: Topalian Role: Co-Investigator; 2% effort Notes: This study will correlate clinical outcomes with biomarkers in the tumor microenvironment of kidney cancer patients receiving nivolumab (anti-PD-1, BMS-936558) therapy on 3 clinical trials 12/01/09-11/30/14, Tumor Necrosis Superfamily Ligands and Lymphocytes Role in Liver Regeneration R01 DK080736 NIDDK $1,443,212 TDC PI: Anders Role: PI, 16% effort Notes: The goal of this project is to first, aim to show what cell survival mechanisms the lymphotoxin beta receptor triggers. Second, link the production of interleukin 6 and stimulation of STAT3 phosphorylation to the lymphotoxin receptor. Third, specifically tie the lymphotoxin receptor to the production of IL-6 and the intrahepatic cellular response. Together these aims will define the role of TNF superfamily member in liver regeneration and lead to a better understanding of what causes and could potentially prevent liver injury. 04/05/10-01/31/17 R01 DK080736 NIDDK No Cost Extension PI: Anders Role: PI; 5% effort Note:Tumor Necrosis Superfamily Ligands and Lymphocytes Role in Liver Regeneration The goal of this project is to first, aim to show what cell survival mechanisms the lymphotoxin beta receptor triggers. Second, link the production of interleukin 6 and stimulation of STAT3 phosphorylation to the lymphotoxin receptor. Third, specifically tie the lymphotoxin receptor to the production of IL-6 and the intrahepatic cellular response. Together these aims will define the role of TNF superfamily member in liver regeneration and lead to a better understanding of what causes and could potentially prevent liver injury.


11/1/2014-10/31/2016 BMSC192 Bristol Myers Squibb $168,042 PI: Topalian Role: Co-Investigator; 2% Note: Analysis of PD-1 Blockade in Virus-Associated Cancers The goal of this project is to further investigate the blockade of the immune cell inhibitory receptor programmed death-1 (PD-1) on tumor cells 09/14/11-07/31/16 R01 CA150142 NIH/NCI $206,687 PI: Matsui Role: Co-Investigator; 5% effort Note: Cellular Diversity and Clinical Relevance of Stem Cells in Pancreatic Cancer The goal of this project is to define the relationship between distinct cancer stem cell populations in pancreatic cancer.

Research Program Building/Leadership N/A

EDUCATIONAL ACTIVITIES

Educational Publications Invited Reviews 1. Anders RA, Kamel IR. Biopsy considerations in the diagnosis of hepatic masses. Clinical Gastroenterology and Hepatology. 2007 May;5(5):541-4. PMID: 17478344 2. Anders RA, Montgomery EM, Maitra A. Johns Hopkins course: 8th annual Current Topics in Gastrointestinal and Liver Pathology. Expert Review of Gastroenterology & Hepatology. 2009 Feb;3(1):33-7. PMID: 19210111 Case Reports 1. Anders RA, Keith JN, Hart J. Rosai-Dorfman disease presenting in the gastrointestinal tract. Archives of Pathology & Laboratory Medicine. 2003 Feb;127(2). PMID: 12562257 2. Karfouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clinical Gastroenterology and Hepatology. 2007 Jul;5:809-812. Epub 2007 May 16. PMID: 17509944 3. Wheeler YY, Wheeler GL, Diaz-Arias AA, Anders RA. Metastatic renal cell carcinoma within hepatic focal nodular hyperplasia: a case report and review of literature. International Journal of Clinical and Experimental Pathology. 2009;2(2):190–193. Epub 2008 Jun 9. PMID: 19079655. PMCID: PMC2583637

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17478344&query_hl=30&itool=pubmed_docsum


4. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM. Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Digestive Disease and Science. 2010 Nov;55(11):3052-8. PMID: 20108035 5. Venkataramani M, Hutton N, Colombani P, Anders RA, Agwu AL. Hepatocellular carcinoma in a teenager with perinatally acquired HIV Infection without hepatitis B or C coinfection: a case report. AIDS Patient Care and STDS. 2010 Nov;24(11):693-6. Epub 2010 Oct 23. PMID: 20969466. PMCID: PMC2994537 Book Chapters 1. Section on neoplasia and microarray technology. Neoplasia Chapter in Pathologic Basis of Disease 6th Ed. Cotran, Kumar and Collins. 2. Chapter on Duodenal Anatomy. Encyclopedia of Gastroenterology 1st Ed. Editor Leonard R. Johnson. Academic Press. 2004; Pg 655. 3. Chapter on Pathology of Technical Complications in Liver Transplantation, Pathology of Solid Organ Transplantation. Ed. H.Liapis and H.L. Wang. Springer-Verlag. 2011.

Teaching: Classroom 1997-2003 Pathology Organ Review Discussion

leader University of Chicago Medical School

2001 Department of Pathology Fellows Conference

Lecturer University of Chicago Medical School

2001 Acute Colitis Lecturer University of Chicago Medical School

2001 Liver Biopsy Vascular Lesions

Lecturer University of Chicago Medical School

2001 Pathology Board Review Lecturer University of Chicago Medical School

12/13/2005-01/05/2005

GI and Liver Pathology Discussion leader; 16 hrs. contact time

Johns Hopkins Medical School

01/04/2005 Chronic Hepatitis; Second Year Pathology Course

Lecturer; 1 hr. contact time

Johns Hopkins Graduate School

12/14/2005 Gastrointestinal System, Pathobiology Course



07/22/2006 Chronic Hepatitis. Pathology Residents


Johns Hopkins School of Medicine


Lecturer; 2 hrs. contact time


09/15/2006 Tissue Repair Mechanisms, Pathobiology Course








Lecturer; 1.5 hrs. contact time


09/17/2007 Tissue Repair Mechanisms, Pathobiology Course



05/01/2008 Hepatology Residency Conference; Approach to Chronic Hepatitis


Johns Hopkins Medical School

08/27/2008 Digestive Tract and Liver and Pancreas Biology and Pathology; Pathobiology Course



08/27/2009 Digestive tract Gross Lab; Pathobiology Course

Discussion leader; 1 hr. contact time


10/03/2008 Patholobiology Diagnosis Competition; Pathobiology Course

Discussion leader; 1 hr. contact time


01/14/2009 Hepatitis Lecturer; 1 hr. contact time


01/05/2009-01/16/2009

GI and Liver Pathology Pathophysiology Course

Discussion leader; 16 hrs. contact time


03/30/2009 Liver and Pancreatic Cancer Pathology. Patholobiology of Cancer



04/22/2009 Grant writing 101. Administrative Considerations



05/05/2009 Pathology of the Biliary System, Cholangiocarcinoma. Resident Education Oncology Conference



08/28/2009 Functional Histology of the GI Tract.


Johns Hopkins Pathobiology Graduate School

09/25/2009 Tissue Repair Lecturer; 2 hrs. contact time

Johns Hopkins Pathobiology Graduate School

1/13/2010 Normal Liver Anatomy and Injury Patterns



11/2/ 2010 – 1/20/2010

GI and Liver Patholophysiology




4/19/2010 Road Blocks and Regulations in Grant Writing



3/23/2011 Liver and Pancreatic Cancer Lecture; 1 hr contact time


3/25/2011 Road Blocks to Grant Submission

Lecture; 1 hr contact time


11/10/2011 – 12/2/2011

Genes to Society GI / Liver Section



11/05/2012-11/30/2012


Director and Discussion Leader, 20 hrs. contact time


11/18/2013 Introduction to Hepatobiliary Histology

Lecturer, 1 hour contact time


11/22/2013 Hepatobiliary Tumors Lecturer, 1 hour contact time


12/04/2013-11/26/2013


Director and Discussion Leader, 20 hrs. contact time


03/25/2014 Pancreatic Cancer 101 Lecturer, 45 minutes contact time


03/25/2014 Liver Cancer Basics Lecturer, 45 minutes contact time


04/26/2014 Road Blocks and Obstacles Lecturer, 1 hour contact time


CME 2004 4th Current Topics in

Gastrointestinal Pathology Lecturer Baltimore, MD

2005 5th Current Topics in Gastrointestinal Pathology

Lecturer Baltimore, MD


Director & Lecturer

Baltimore, MD


Director & Lecturer

Baltimore, MD


Director & Lecturer

Baltimore, MD


Director Baltimore, MD


Director & Lecturer

Baltimore, MD

2011 11th Current Topics in Director & Baltimore, MD


Gastrointestinal Pathology Lecturer 2012 12th Current Topics in

Gastrointestinal Pathology Director & Lecturer

Baltimore, MD


Director & Lecturer

Baltimore, MD

Mentoring: Pre-Doctoral Research Advisees (Univ. of Chicago)

Peter Christiansen 6/02-6/05 Current Position: Southern Illinois Medical Student

Pre-Doctoral Research Advisees (JHU)

Paul Markowski 4/06-9/06 Current Position: Robert Wood Johnson Medical student Studied liver fibrosis while a student in the Howard Hughes Summer Research

Program and Mena Bekhit 6/09-8/09 Current Position: University of Florida Medical student Studied liver injury while a student in the Leadership Alliance Summer Research

Program Suresh K. Nayar 6/11-8/12 Current Position: Medical student Johns Hopkins School of Medicine

Post-Doctoral Research Advisees (JHU)

Marianna Fathy Kamel, M.D. 1/06-5/07 Current Position: Minia University Egypt Attending Pathologist 1/06 - Hippo pathway contribution to hepatocellular carcinoma. Angela Steinhardt, M.D. 6/07-10/07 Current Position: Resident pathologist Brigham and Women’s Hospital 6/07 - Yes-associated protein expression in solid tumors. Ikumi Kayama, M.S. 1/07-4/08 Current Position: Elsevier Publishing 4/08 - Master of Art Thesis. Art as Applied to Medicine. Topic: Visualizing the

regenerating liver. Haibo Bai, Ph.D. 2/07-04/14 Current position: Assistant Professor, Temple University 4/07 - Hippo pathology in liver disease. Yang Xu, M.D. Ph.D. 3/10-12/11 Current position: Pathobiliary Surgeon, Fudan University 3/10 – Hepatocellular Carcinoma. Haixiang Sun, M.A. 9/10-5/11


Current position: D.Sc. Candidate, Fudan University 9/10 – Liver cancer. Qingfeng Zhu, Ph.D. 09/11-present Current position: GI and Liver Pathology Post Doc

09/11 - Molecular Basis of Intrahepatic Cholangiocarcinoma Ying Liu,M.D. 01/13-01/14 Current position: Postdoctoral Fellow, Johns Hopkins University 01/13 – Molecular Aspects of Pancreatic and Liver Cancer

Pathology Residency Advisees (Univ of Chicago)

Lisa Yerian, M.D. 6/02-5/03 Current Position: Cleveland Clinic, Attending Pathologist 6/02 - Studies in Hepatic Dysplastic Nodules.

Pathology Residency Advisees (JHU)

Janis Taube, M.D. 1/07-4/08 Current Position: Faculty, Johns Hopkins Department of Dermatopathology B7-H1 expression in melanoma. Julie Katz-Karp, M.D. 4/07-6/10 Current Position: Faculty, Department of Pathology, Jefferson University Autoimmune hepatitis in primary Sjogrens syndrome. William Savage M.D. Ph.D. 7/09-7/11 Current Position: Faculty Brigham and Women’s Hospital Hepatic consequences of transfusion iron overload Brent Orr, M.D., Ph.D. 7/08-7/12 Current Position: Faculty St. Jude’s Children’s Hospital Research advisor and mentor in studies of Baojin Fu, M.D., Ph.D. 1/08-7/12 Current position: Resident, Johns Hopkins Department of Pathology

Clinical Fellow Advisees: Gastrointestinal Pathology Fellowship

Jon Davison, M.D. 7/05-6/06 Mehmet Guler, M.D. 1/06-6/07 Jason Daniels, M.D. 7/06-6/08 Zong Min-Chen, M.D., Ph.D. 7/07-6/08 Jennifer Scuidere, M.D. 7/07-6/09 Thong Nguyen, D.O. 7/08-5/09 Jason Park, M.D., Ph.D. 7/08-6/10 Dora Lam-Himlin, M.D. 7/09-6/10 Chanjuan Shi, M.D. 7/09-6/10 Toby Cornish, M.D., Ph.D. 7/09-6/11 Ming-Tseh Lin, M.D., Ph.D. 7/09-6/10 Christina Arnold, M.D. 7/10-6/12


Karen Matsukuma, M.D., Ph.D. 7/10-6/12 Aatur Singhi, M.D., Ph.D. 7/11-6/12 Ta-Chiang Liu, M.D., Ph.D. 7/11-6/12 Oliver McDonald, M.D., Ph.D. 7/11-6/13 Laura Wood, M.D., Ph.D. 7/12-6/13 Safia Salaria, M.D. 7/12-6/13 Michael Cruise, M.D., Ph.D. 7/12-present Sabrina Wentz, M.D. 7/13-present Arvind Rishi, M.B.B.S. 7/13-present Changquing Ma, M.D. 7/13-present

PhD Thesis Committees (JHU)

Melissa Landek-Salgado, Advisor: P Caruregli Current Position: Pathobiology graduate student Basic mechanisms of autoimmune disease in mice. DJ Jhaveri, Advisor: L. Jaffee Current Position: Pathobiology graduate student

Pediatric GI Research Committee (JHU) Stefany Honigbaum, Advisor: Kathleen Swarz

Educational Program Building/Leadership 2010-present Pathobiology Graduate School Executive Committee Educational Extramural Funding N/A

CLINICAL ACTIVITIES

Certification: Licensure 1998 Illinois Medical License, inactive 2005-current Maryland Medical License, active Boards 2002 Diplomate of the American Board of Pathology in Anatomic & Clinical

Pathology

Service Responsibilities: 2003-2004 Gastrointestinal and liver pathology sign out. University of Chicago Hospitals 2005 845 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital 2006 1719 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital 2007 1433 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital 2008 1713 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital 2009 1758 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital 2010 1458 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital 2011 1658 cases Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital


2012-present Gastrointestinal and liver pathology sign out. Johns Hopkins Hospital

Clinical Program Building/Leadership N/A Clinical Extramural Funding N/A

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation and Quality Improvement Publications N/A System Innovation and Quality Improvements outside of JHM N/A Production of Guidelines and/or Protocols N/A System Innovation and Quality Improvement Program Building/Leadership N/A System Innovation and Quality Improvement Extramural Funding N/A

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments: 2007-present Member, Pathology Residency Training Program Committee

Editorial Activities: Ad hoc reviewer 2008 Modern Pathology, Laboratory Investigation 2009 America Journal of Pathology, Annals of Surgical Oncology, Expert Opinion on

Therapeutic Targets 2010 Oncogene, Journal of Gastrointestinal Cancer, American Journal of Pathology,

International Journal of Immunogenetics 2011 Annals of Surgical Oncology, Gastroenterology, Human Pathology, International

Journal of Oral Science, Lab Investigation, Molecular Cancer Therapeutics 2012 Gastroenterology, Hepatology, Journal of Clinical Investigation, Expert Opinions on

Therapeutic Targets, Molecular Cancer Therapeutics 2013 Gastroenterology, Lab Investigation, PLOS, Modern Pathology 2014 Gastroenterology, Lab Investigation, Modern Pathology, Cancer Immunology

Research Editorial Board appointments: 07/06-07/09 Journal of Laboratory Investigation


04/08-current International Journal of Experimental and Clinical Pathology 04/09-current Cancers 02/14-current World Journal of Hepatology

Advisory Committees, Review Groups/Study Sections: NIH Study Sections 10/05/2009-10/06/2009 NIDDK Ad Hoc Reviewer NIH Digestive, Kidney and

Urologic Systems (NIDDK). Hepatobiliary Pathophysiology Study Section. San Fransico, CA.

11/17/2009 NIDDK Ad Hoc Reviewer NIH Digestive, Kidney and

Urologic Systems (NIDDK). Center for Scientific Review SBIR. Bethesda, MD. 11/21/2013-11/22/2013 NIDDK Ad Hoc Reviewer Special Emphasis Panel.

Bethesda, MD. 04/03/2014-04/04/2014 NIDDK Ad Hoc Reviewer Special Emphasis Panel.

Bethesda, MD.

Professional Societies: Member Rodger C. Haggitt GI Pathology Society Member United States and Canadian Academy of Pathology Member American Gastroenterological Association Member College of American Pathology Member American Association for the Study of Liver Diseases Member American Gastroenterological Association Member Member American Association for Cancer Research

Conference Organizer, Session Chair 2006 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2007 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2008 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2009 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2010 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2011 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2012 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course 2013 Johns Hopkins Director Current Topics in Gastrointestinal Pathology CME course

Consultantships: 1999-2000 Atrionix Corp. 2000-2003 CryoCath Inc. Consulting pathologist performing histologic assessment of cardiac tissues

following treatment with experimental cardiac catheters 2003 SphincTx Medical Inc. Consulting pathologist performing histologic assessment of the

gastroesophageal junction following treatment with experimental catheters


2009 Millennium Pharmaceuticals Consulting pathologist regarding mechanism of liver injury in animals in

humans treated with experimental oncology drugs RECOGNITION

Awards, Honors: 1990 University of Illinois, Chicago Honors College Tuition Scholarship 1997 Microbiology and Pulmonary Infection Travel Award, American Thoracic

Society 2000 Lemuel Bowie Young Investigator Award, American Association for Clinical

Chemistry

Invited Talks, Panels: 2000 Gastrointestinal cytopathology. University of Chicago Cytopathology Resident

Lectures. 2002 Real-Time reverse transcription PCR validation of microarray data. University of

Chicago Bioinformatics Workshop. 2002 Updates in molecular diagnostics. The 15th Annual Association of Medical

Laboratory Immunologists Conference. 2002 Gene expression and laser microdissection: Focus on real-time RT-PCR. Laser

Capture Microdissection Core Facility Workshop.

2003 Works in progress: Liver regeneration and the immune system. Committee on Immunology

2003 An overview of quantitative real-time PCR. International Microarray Workshop. 2004 Fourth annual Current Topics in Gastrointestinal Pathology: Practical approach

to the diagnosis of liver tumors. Baltimore, MD. 2005 Fifth Annual Current Topics in Gastrointestinal Pathology: Practical Review of

Hepatic Masses and Chronic Liver Disease. Baltimore, MD. November 7th. 2005 Immunologic aspects of liver disease: Liver regeneration and T cell hepatitis.

Baltimore, MD. November 30th. 2006 Sixth Annual Current Topics in Gastrointestinal Pathology: Chronic Liver

Disease. Baltimore, MD. October 6th. 2007 Johns Hopkins Department of Pathology Grand Rounds, It Keeps Growing and

Growing. Understanding Liver Growth Control Mechanisms. March 5th.


2007 Chronic Hepatitis Critical Evaluation of HCV Liver Biopsies, 7th Annual Conference Current Issues in Diagnostic Pathology, University of Chicago Nov 2nd

2007 Practical Approach to the Diagnosis of Liver Tumors, Chronic Hepatitis Critical

Evaluation of HCV Liver Biopsies, 7th Annual Conference Current Issues in Diagnostic Pathology, University of Chicago Nov 2nd

2007 Inflammatory Patterns in Liver Disease, ASCP, Surgical Pathology Series,

Teleconference series, Dec. 7th 2007 2009 GI and Liver Surgical Pathology Conference, University of Chicago, April 9th

2009. 2011 Investigation into biliary atresia, BARC pathology meeting. January 15-16th,

2011. Houston TX 2011 Hippo signaling pathway in liver development and regeneration. Digestive

Disease Week. Cholangiocyte Biology and Bile Formation Session Moderator and Presenter: May 8th, 2011 Chicago IL.

2011 “From Fat Flies to Large Livers” Liver Regeneration. Mayo Clinic

Transplantation Grand Rounds. May 2nd 2011. Rochester MN. 2011 Hippo Pathway in Liver Injury and Development University of Pittsburgh,

Pathology Seminar Series May 5th 2011. Pittsburgh PA. 2012 Hepatobiliary Obstruction. Medical Education for Services to All Ugandans

Grand Rounds. Video Conference Panel Member. June 19th 2012. Baltimore MD and Makerere Hill Uganda.

2013 The Hippo Pathway: From Fat Flies to Huge Livers. Johns Hopkins University

Pathology Grand Rounds, April 4th, 2013. Baltimore MD. 2014 Antibodies as Mediators of Anti-Tumor Immunity. 10th Annual PEGS: The

Essential Protein Engineering Summit, Antibodies of Cancer Therapy track, May 5th through 9th, 2014. Boston MA.

2014 Tissue and Serum Derived Biomarkers. SWOG Spring Meeting, Immunology

Biomarkers Workshop, May 2nd, 2014. San Francisco CA

business address: 1550 orleans street crb-2 room 345 · curriculum vitae for academic promotion the...

Documents